<DOC>
	<DOCNO>NCT00002779</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy hormone therapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . PURPOSE : Phase II trial study effectiveness fludarabine plus octreotide treating patient relapse low-grade non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Fludarabine Plus Octreotide Treating Patients With Relapsed Low-Grade Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate duration response fludarabine combine octreotide octreotide alone patient relapsed indolent non-Hodgkin 's lymphoma . II . Determine serum insulin-like growth factor-1 ( IGF-1 ) IGF-1 bind protein level treatment patient population . III . Determine somatostatin receptor subtypes lymphoma biopsy sample select patient . OUTLINE : Patients receive fludarabine IV 10-30 minute day 1-5 . Patients currently receive octreotide , receive test dose octreotide subcutaneously day 1 course 1 receive octreotide intramuscularly monthly day 1 . Treatment repeat every 28 day 4-6 course . Patients receive octreotide alone 6-8 course . Some patient may receive another 12 course octreotide alone , total 2 year treatment . Patients follow every 3 month 5 year disease progression .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically diagnose indolent nonHodgkin 's lymphoma ( NHL ) 1 follow type : Diffuse small lymphocytic cell Follicular small cleave cell Follicular mix small large cleave cell Mantle cell lymphoma/leukemia ( intermediate differentiate lymphoma ) Preferentially treat protocol NCCTG958053 available Monocytoid Bcell Mucosaassociated lymphoid tissue ( MALT ) Lymphoplasmacytic lymphoma ( Waldenstrom 's macroglobulinemia ) Histology document lymph node ( mass ) bone marrow biopsy within 6 month prior entry Relapsed cytotoxic chemotherapy regimens At least 1 measurable lesion palpation , chest xray , CT , MRI , e.g . : Lymph node least 1.5 x 1.5 cm palpation Spleen least 3 cm leave costal margin The following exclude : CNS involvement positive CSF cytology CT/MRI B Tcell chronic lymphocytic leukemia Hairy cell leukemia Mycosis fungoides Aggressive lymphoma PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Total bilirubin great 2 time normal OR Direct bilirubin great 1.0 mg/dL normal Renal : Creatinine great 2.0 time normal Cardiovascular : No uncontrolled congestive heart failure No uncontrolled hypertension No uncontrolled angina pectoris Other : No uncontrolled active infection No AIDS HIV antibody No second malignancy within 5 year except : Carcinoma situ cervix Resected nonmelanomatous skin cancer Prostate cancer remission follow radical retropubic prostatectomy radiotherapy Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Recovered toxic effect prior therapy Biologic therapy : See Disease Characteristics No concurrent interferon Chemotherapy : See Disease Characteristics No prior purine nucleoside analogue ( e.g. , fludarabine , pentostatin , 2 chlorodeoxyadenosine ) At least 3 week since prior chemotherapy ( 6 week since nitrosoureas ) No concurrent cytotoxic chemotherapy Endocrine therapy : No prior octreotide lymphoma No concurrent corticosteriods except Addison 's disease Radiotherapy : Not specify Surgery : Not specify Other : No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Waldenstr√∂m macroglobulinemia</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
</DOC>